Advanzeon Solutions Competitors

Advanzeon Solutions (OTCMKTS:CHCR) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Profitability

This table compares Advanzeon Solutions and Reviva Pharmaceuticals' net margins, return on equity and return on assets.

Risk and Volatility

Advanzeon Solutions has a beta of 2.76, suggesting that its stock price is 176% more volatile than the S&P 500. Comparatively, Reviva Pharmaceuticals has a beta of -0.04, suggesting that its stock price is 104% less volatile than the S&P 500.

Earnings and Valuation

This table compares Advanzeon Solutions and Reviva Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Reviva Pharmaceuticals has lower revenue, but higher earnings than Advanzeon Solutions.

Institutional & Insider Ownership

64.1% of Reviva Pharmaceuticals shares are held by institutional investors. 16.5% of Advanzeon Solutions shares are held by company insiders. Comparatively, 20.6% of Reviva Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for Advanzeon Solutions and Reviva Pharmaceuticals, as provided by MarketBeat.

Summary

Reviva Pharmaceuticals beats Advanzeon Solutions on 5 of the 8 factors compared between the two stocks.

Advanzeon Solutions (OTCMKTS:CHCR) and Bellerophon Therapeutics (NASDAQ:BLPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

Profitability

This table compares Advanzeon Solutions and Bellerophon Therapeutics' net margins, return on equity and return on assets.

Volatility and Risk

Advanzeon Solutions has a beta of 2.76, suggesting that its stock price is 176% more volatile than the S&P 500. Comparatively, Bellerophon Therapeutics has a beta of -0.29, suggesting that its stock price is 129% less volatile than the S&P 500.

Valuation and Earnings

This table compares Advanzeon Solutions and Bellerophon Therapeutics' revenue, earnings per share (EPS) and valuation.

Advanzeon Solutions has higher revenue and earnings than Bellerophon Therapeutics.

Institutional and Insider Ownership

40.2% of Bellerophon Therapeutics shares are held by institutional investors. 16.5% of Advanzeon Solutions shares are held by company insiders. Comparatively, 38.5% of Bellerophon Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Advanzeon Solutions and Bellerophon Therapeutics, as provided by MarketBeat.

Bellerophon Therapeutics has a consensus price target of $26.50, suggesting a potential upside of 444.15%. Given Bellerophon Therapeutics' higher possible upside, analysts clearly believe Bellerophon Therapeutics is more favorable than Advanzeon Solutions.

Summary

Bellerophon Therapeutics beats Advanzeon Solutions on 6 of the 10 factors compared between the two stocks.

Advanzeon Solutions (OTCMKTS:CHCR) and Cyclo Therapeutics (NASDAQ:CYTH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

Profitability

This table compares Advanzeon Solutions and Cyclo Therapeutics' net margins, return on equity and return on assets.

Volatility and Risk

Advanzeon Solutions has a beta of 2.76, suggesting that its stock price is 176% more volatile than the S&P 500. Comparatively, Cyclo Therapeutics has a beta of -1, suggesting that its stock price is 200% less volatile than the S&P 500.

Valuation and Earnings

This table compares Advanzeon Solutions and Cyclo Therapeutics' revenue, earnings per share (EPS) and valuation.

Advanzeon Solutions has higher earnings, but lower revenue than Cyclo Therapeutics.

Institutional and Insider Ownership

2.4% of Cyclo Therapeutics shares are held by institutional investors. 16.5% of Advanzeon Solutions shares are held by company insiders. Comparatively, 31.9% of Cyclo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Advanzeon Solutions and Cyclo Therapeutics, as provided by MarketBeat.

Cyclo Therapeutics has a consensus price target of $25.00, suggesting a potential upside of 241.53%. Given Cyclo Therapeutics' higher possible upside, analysts clearly believe Cyclo Therapeutics is more favorable than Advanzeon Solutions.

Summary

Cyclo Therapeutics beats Advanzeon Solutions on 7 of the 11 factors compared between the two stocks.

Advanzeon Solutions (OTCMKTS:CHCR) and NLS Pharmaceutics (NASDAQ:NLSP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

Profitability

This table compares Advanzeon Solutions and NLS Pharmaceutics' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Advanzeon Solutions and NLS Pharmaceutics' revenue, earnings per share (EPS) and valuation.

NLS Pharmaceutics has lower revenue, but higher earnings than Advanzeon Solutions.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Advanzeon Solutions and NLS Pharmaceutics, as provided by MarketBeat.

NLS Pharmaceutics has a consensus price target of $10.6667, suggesting a potential upside of 175.62%. Given NLS Pharmaceutics' higher possible upside, analysts clearly believe NLS Pharmaceutics is more favorable than Advanzeon Solutions.

Summary

NLS Pharmaceutics beats Advanzeon Solutions on 4 of the 5 factors compared between the two stocks.

Advanzeon Solutions (OTCMKTS:CHCR) and Jupiter Wellness (NASDAQ:JUPW) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Advanzeon Solutions and Jupiter Wellness, as provided by MarketBeat.

Profitability

This table compares Advanzeon Solutions and Jupiter Wellness' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Advanzeon Solutions and Jupiter Wellness' revenue, earnings per share (EPS) and valuation.

Jupiter Wellness has lower revenue, but higher earnings than Advanzeon Solutions.

Summary

Jupiter Wellness beats Advanzeon Solutions on 2 of the 3 factors compared between the two stocks.

F-star Therapeutics (NASDAQ:FSTX) and Advanzeon Solutions (OTCMKTS:CHCR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares F-star Therapeutics and Advanzeon Solutions' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares F-star Therapeutics and Advanzeon Solutions' top-line revenue, earnings per share and valuation.

Advanzeon Solutions has higher revenue and earnings than F-star Therapeutics.

Institutional and Insider Ownership

67.8% of F-star Therapeutics shares are owned by institutional investors. 12.7% of F-star Therapeutics shares are owned by insiders. Comparatively, 16.5% of Advanzeon Solutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

F-star Therapeutics has a beta of 1.78, meaning that its share price is 78% more volatile than the S&P 500. Comparatively, Advanzeon Solutions has a beta of 2.76, meaning that its share price is 176% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for F-star Therapeutics and Advanzeon Solutions, as provided by MarketBeat.

F-star Therapeutics presently has a consensus target price of $33.50, suggesting a potential upside of 221.50%. Given F-star Therapeutics' higher possible upside, equities analysts clearly believe F-star Therapeutics is more favorable than Advanzeon Solutions.